From a safety perspective, the most commonly observed adverse effects associated with BYL719 were hyperglycemia, nausea, fatigue, rash and gastrointestinal toxicities [25], all of which are also frequently encountered with the pan-PI3K inhibitors. Here, PIK3CD is linked to Hyperglycemia.